Your activity: 8 p.v.
< Back

Selected trials of systemic chemotherapy for metastatic pancreatic neuroendocrine tumors

Selected trials of systemic chemotherapy for metastatic pancreatic neuroendocrine tumors
Regimen Number of patients* Tumor response rate (%) Median progression-free survival (months) Median overall survival (months) Author; year
Prospective studies
Chlorozotocin 33 30 17 18.0 Moertel C; 1992
Fluorouracil + streptozocin 33 45 14 16.8
Doxorubicin + streptozocin 36 69 18 26.4
Dacarbazine (DTIC) 50 34 NR 19.3 Ramanathan R; 2001
Temozolomide + thalidomide 11 45 NR NR Kulke M; 2006
Temozolomide + bevacizumab 15 33 14.3 41.7 Chan JA; 2012
Temozolomide + everolimus 40 40 15.4 NR Chan JA; 2013
Temozolomide + capecitabine 72 33 22.7 not reached Kunz PL; 2018
Temozolomide 72 28 14.4 38
Retrospective series
Steptozocin + doxorubicin + fluorouracil 84Δ 39 18 37 Kouvaraki M; 2004
Temozolomide (diverse regimens) 53 34 13.6 35.3 Kulke M; 2009
Streptozocin + fluorouracil 96 43 19.4 54.8 Dilz LM; 2015
Temozolomide (single agent) 12 8 NR NR Ekeblad S; 2007
Temozolomide + capecitabine 30 70 18 NR Strosberg J; 2011
NR: not reported.
* Number of patients evaluable for efficacy endpoints.
¶ Combined biochemical and radiologic response rate.
Δ Includes patients with locally advanced disease.
Graphic 63537 Version 11.0